GoAI
Get started
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc.

CADL

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$13.13

+$0.78 · +6.32%

Aug 21, 4:00 PM ET

CADL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

40

Expensive

Momentum

68

Gaining

Sentiment

35

Bearish

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Paul-Peter Tak
Listed since
Jul 27, 2021
Employees
55

Market position

Day range

Current $13.13

52-week range

Current $13.13

Open
$12.52
Previous close
$12.35
Volume
1.34M
0.72× average
Average volume
1.87M
Average daily volume
Market cap
962.04M USD
Beta
-0.5
Market reference 1
50-day average
$10.072
+30.36% above average
200-day average
$6.9797
+88.12% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
181.39M USD
P/E (TTM)
-9.31×
P/B (TTM)
7.72×
P/S (TTM)
0×
EV / EBITDA
-5.15×
Earnings yield
-12.76%
Free cash flow yield
-13.00%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-73.54%
Return on assets
-30.50%
Return on invested capital
-41.38%

Financial health

Debt / equity
0.39×
Current ratio
13.31×
Altman Z-score
4.94
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends3000%-8600%-20199%-31799%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Operating margin, FY2021: -20580.80%Operating margin, FY2022: -27739.20%Net margin, FY2021: -28899.20%Net margin, FY2022: -15035.20%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Operating margin FY2021 -20580.80%. Operating margin FY2022 -27739.20%. Net margin FY2021 -28899.20%. Net margin FY2022 -15035.20%.

Income trends

Revenue

125K USD0.00%

Operating income

−48.27M USD-44.63%

Net income

−38.18M USD+30.80%
Income trends across reported periods5.66M USD−16.47M USD−38.59M USD−60.71M USDRevenue, FY2021: 125K USDRevenue, FY2022: 125K USDOperating income, FY2021: −25.73M USDOperating income, FY2022: −34.67M USDOperating income, FY2023: −38.39M USDOperating income, FY2024: −33.37M USDOperating income, FY2025: −48.27M USDNet income, FY2021: −36.12M USDNet income, FY2022: −18.79M USDNet income, FY2023: −37.94M USDNet income, FY2024: −55.18M USDNet income, FY2025: −38.18M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 125K USD. Revenue FY2022 125K USD. Operating income FY2021 −25.73M USD. Operating income FY2022 −34.67M USD. Operating income FY2023 −38.39M USD. Operating income FY2024 −33.37M USD. Operating income FY2025 −48.27M USD. Net income FY2021 −36.12M USD. Net income FY2022 −18.79M USD. Net income FY2023 −37.94M USD. Net income FY2024 −55.18M USD. Net income FY2025 −38.18M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue———125K USD125K USD
Gross profit———125K USD125K USD
Research and development30.5M USD19.31M USD24.51M USD20.79M USD15.18M USD
Selling, general, and administrative17.77M USD14.06M USD13.89M USD14.06M USD10.67M USD
Operating expenses48.27M USD33.37M USD38.39M USD34.8M USD25.85M USD
Interest income3.92M USD1.09M USD2.08M USD1.22M USD—
Interest expense2.12M USD2.09M USD2.6M USD1.71M USD—
Depreciation and amortization845K USD990K USD960K USD778K USD—
Operating income−48.27M USD−33.37M USD−38.39M USD−34.67M USD−25.73M USD
Net income−38.18M USD−55.18M USD−37.94M USD−18.79M USD−36.12M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
38%
3 beats, 5 misses, 0 met estimates
Average EPS surprise
-30.11%
8 comparable reports
Latest EPS result
-0.52
Estimate -0.24 · Miss by 118.55%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.18-0.08-0.33-0.59Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual -0.4, estimate -0.23, surprise -73.91%, Miss. Q2 2025, reported May 13, 2025: actual 0.13, estimate -0.24, surprise +154.17%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.09, estimate -0.17, surprise +47.06%, Beat. Q4 2025, reported Nov 13, 2025: actual -0.21, estimate -0.17, surprise -23.53%, Miss. Q1 2026, reported Mar 12, 2026: actual -0.54, estimate -0.24, surprise -125.00%, Miss. Q2 2026, reported May 14, 2026: actual -0.14, estimate -0.22, surprise +36.36%, Beat. Q3 2026, reported Aug 13, 2026: actual -0.52, estimate -0.238, surprise -118.55%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.3, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$22.50

71.36% upside
Past 12 months12-month forecastHigh $23.00Average $22.50Low $22.00

Rating distribution

10 ratings
Strong buy00%
Buy990%
Hold110%
Sell00%
Strong sell00%

Recent analyst actions

6 institutions
Stephens & Co.maintainOverweight
Freedom BrokermaintainBuy

CADL news

seekingalpha.com

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring…

Read source
globenewswire.com

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve…

Read source
marketbeat.com

Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up

Candel Therapeutics NASDAQ: CADL is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief Scientific Officer…

Read source
seekingalpha.com

Candel Therapeutics: Getting Closer, And Building Out More Paths

Candel Therapeutics, Inc. remains a Buy as its lead asset, CAN-2409, advances toward FDA submission in prostate cancer with strong phase 3 data. CADL is well-capitalized, holding $194.8M in cash, providing runway into Q1…

Read source
globenewswire.com

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve…

Read source
globenewswire.com

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve…

Read source

CADL peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CADL

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
26.24M
Weight
0.23%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
20.07M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
19.7M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
6.87M
Weight
0.05%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
6.61M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
5.33M
Weight
0.05%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
3.56M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
State Street SPDR S&P Kensho New Economies Composite ETF logoState Street SPDR S&P Kensho New Economies Composite ETFKOMP
Market value
3.24M
Weight
0.12%
AUM
2.71B USD
Expense ratio
0.20%
Price / 1D
$69.24+0.92%

Continue in GoAI

Research CADL

research.disclaimer